These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 7937285)
1. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Smith CL; Hampton EM; Pederson JA; Pennington LR; Bourne DW Pharmacotherapy; 1994; 14(4):471-81. PubMed ID: 7937285 [TBL] [Abstract][Full Text] [Related]
2. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257 [TBL] [Abstract][Full Text] [Related]
3. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function. Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of sirolimus in kidney transplant patients. Ferron GM; Mishina EV; Zimmerman JJ; Jusko WJ Clin Pharmacol Ther; 1997 Apr; 61(4):416-28. PubMed ID: 9129559 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C; Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038 [TBL] [Abstract][Full Text] [Related]
6. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Sketris IS; Methot ME; Nicol D; Belitsky P; Knox MG Ann Pharmacother; 1994 Nov; 28(11):1227-31. PubMed ID: 7849332 [TBL] [Abstract][Full Text] [Related]
7. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. Bunnag S; Vareesangthip K; Ong-ajyooth L J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476 [TBL] [Abstract][Full Text] [Related]
9. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679 [TBL] [Abstract][Full Text] [Related]
10. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Aros CA; Ardiles LG; Schneider HO; Flores CA; Alruiz PA; Jerez VR; Mezzano SA Transplant Proc; 2005 Oct; 37(8):3364-6. PubMed ID: 16298597 [TBL] [Abstract][Full Text] [Related]
11. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Sagedal S; Asberg A; Hartmann A; Bergan S; Berg KJ Clin Transplant; 1998 Dec; 12(6):553-6. PubMed ID: 9850449 [TBL] [Abstract][Full Text] [Related]
12. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Christians U; Bleck JS; Lampen A; Bader A; Thiesemann C; Kliem V; Repp H; Westhoff-Bleck M; Manns M; Sewing KF Transplant Proc; 1996 Aug; 28(4):2159-61. PubMed ID: 8769186 [No Abstract] [Full Text] [Related]
13. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure. Mahgoub AA; El-Medany AH; Abdulatif AS Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppression in live-related donor renal transplantation. Iman A; Rao M; Juneja R; Jacob CK Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322 [TBL] [Abstract][Full Text] [Related]
15. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636 [TBL] [Abstract][Full Text] [Related]
16. Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. Asberg A; Christensen H; Hartmann A; Berg KJ Clin Transplant; 1998 Oct; 12(5):363-70. PubMed ID: 9787942 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793 [TBL] [Abstract][Full Text] [Related]